Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective multicenter phase II trial
Prospective trial compares event-free survival between stem cell transplant and ruxolitinib in myelofibrosis patients, highlighting outcomes and quality of life.
Key Points
To compare event-free survival between patients receiving stem cell transplantation and those continuing ruxolitinib.
Conducted as a prospective multicenter clinical trial
Enrolled 87 patients with myelofibrosis and assigned to either SCT or continued ruxolitinib
Efficacy endpoints included event-free survival and overall survival
Safety endpoints included toxicity monitoring and quality of life assessment
SCT showed significantly improved event-free survival compared to the ruxolitinib group
SCT associated with 84% reduced risk of death or progression
Quality of life improved over time post-SCT while remaining stable for the ruxolitinib group